ATE242639T1 - Morphogen induzierte nerven wiederherstellung und wiedergutmachung. - Google Patents

Morphogen induzierte nerven wiederherstellung und wiedergutmachung.

Info

Publication number
ATE242639T1
ATE242639T1 AT93918560T AT93918560T ATE242639T1 AT E242639 T1 ATE242639 T1 AT E242639T1 AT 93918560 T AT93918560 T AT 93918560T AT 93918560 T AT93918560 T AT 93918560T AT E242639 T1 ATE242639 T1 AT E242639T1
Authority
AT
Austria
Prior art keywords
neurons
mammal
stimulating
repair
morphogenely
Prior art date
Application number
AT93918560T
Other languages
English (en)
Inventor
David C Rueger
Thangavel Kuberasampath
Hermann Oppermann
Engin Ozkaynak
Roy H L Pang
Charles M Cohen
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27363454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE242639(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of ATE242639T1 publication Critical patent/ATE242639T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/32—Materials or treatment for tissue regeneration for nerve reconstruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
AT93918560T 1992-07-31 1993-07-29 Morphogen induzierte nerven wiederherstellung und wiedergutmachung. ATE242639T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92281392A 1992-07-31 1992-07-31
US2933593A 1993-03-04 1993-03-04
US4051093A 1993-03-31 1993-03-31
PCT/US1993/007231 WO1994003200A1 (en) 1992-07-31 1993-07-29 Morphogen-induced nerve regeneration and repair

Publications (1)

Publication Number Publication Date
ATE242639T1 true ATE242639T1 (de) 2003-06-15

Family

ID=27363454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93918560T ATE242639T1 (de) 1992-07-31 1993-07-29 Morphogen induzierte nerven wiederherstellung und wiedergutmachung.

Country Status (10)

Country Link
EP (1) EP0653942B2 (de)
JP (3) JP4344012B2 (de)
AT (1) ATE242639T1 (de)
AU (1) AU681594B2 (de)
CA (1) CA2141554C (de)
DE (1) DE69333040T3 (de)
DK (1) DK0653942T3 (de)
ES (1) ES2201059T5 (de)
PT (1) PT653942E (de)
WO (1) WO1994003200A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US6506729B1 (en) 1991-03-11 2003-01-14 Curis, Inc. Methods and compositions for the treatment and prevention of Parkinson's disease
US6723698B2 (en) 1991-03-11 2004-04-20 Curis, Inc. Methods and compositions for the treatment of motor neuron injury and neuropathy
US6495513B1 (en) 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
EP0653942B2 (de) * 1992-07-31 2007-03-07 Curis, Inc. Morphogen induzierte nerven wiederherstellung und wiedergutmachung.
AU5129293A (en) * 1992-09-15 1994-04-12 Creative Biomolecules, Inc. 60a protein-induced morphogenesis
DK0698094T3 (da) 1993-05-12 2004-05-03 Inst Genetics Llc BMP-11-sammensætninger
EP1716864A1 (de) * 1993-08-26 2006-11-02 Genetics Institute, LLC Neuronale Regeneration mit menschlichen morphogenischen Knochenproteinen
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US5669407A (en) * 1994-03-24 1997-09-23 Masco Corporation Of Indiana Compression cartridge for a faucet valve assembly
WO1996030038A1 (en) * 1995-03-29 1996-10-03 The Rockefeller University Peptide growth factor having epidermal inducing activity
DE69723429T3 (de) * 1996-03-22 2007-09-20 Curis, Inc., Cambridge Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5928940A (en) * 1996-09-24 1999-07-27 Creative Biomolecules, Inc. Morphogen-responsive signal transducer and methods of use thereof
WO1998018469A1 (en) * 1996-10-31 1998-05-07 Nippon Shinyaku Co., Ltd. Cranial nerve cell protectives
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues
WO1998050060A1 (en) * 1997-05-05 1998-11-12 Creative Biomolecules, Inc. Therapies for acute renal failure
CA2291514C (en) 1997-05-30 2011-07-12 Mariel Therapeutics, Inc. Methods for evaluating tissue morphogenesis and activity
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
PT1131087E (pt) † 1998-11-13 2004-12-31 Curis Inc Metodos de alivio de sintomas de cancro
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
ATE271886T1 (de) 1999-10-15 2004-08-15 Inst Genetics Llc Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
WO2002099037A2 (en) 2001-06-01 2002-12-12 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
JP4654029B2 (ja) 2002-06-17 2011-03-16 トラソス インコーポレイテッド 単一ドメインｔｄｆ関連化合物およびその類似体
CA2897218A1 (en) 2004-06-17 2006-01-26 Thrasos Innovation, Inc. Tdf-related compounds and analogs thereof
US20060014288A1 (en) * 2004-06-23 2006-01-19 Tissuegene, Inc. Nerve regeneration
PT2497780E (pt) 2005-09-20 2015-08-20 Thrasos Innovation Inc Compostos relacionados com tdf e seus análogos
AU2009214629A1 (en) 2008-02-13 2009-08-20 Eric T. Choi BMP-7 for use in treating vascular sclerosis
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
WO2018112362A1 (en) * 2016-12-16 2018-06-21 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
WO2020086580A1 (en) 2018-10-22 2020-04-30 Carlson William D Therapeutic combinations of tdfrps and additional agents and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68929472T2 (de) * 1988-04-08 2004-05-13 Stryker Corp., Kalamazoo Biosynthetische knochenbildende Proteine, und sie enthaltende knochenbildende Vorrichtungen
ES2113857T3 (es) * 1989-03-28 1998-05-16 Genetics Inst Composiciones osteoinductoras.
DE69131580T2 (de) * 1990-06-15 2000-01-13 Carnegie Institution Of Washington, Washington GDF-1 und UOG1 Proteine
AU660019B2 (en) * 1991-03-11 1995-06-08 Stryker Corporation Protein-induced morphogenesis
DE69233022T2 (de) * 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
EP0653942B2 (de) * 1992-07-31 2007-03-07 Curis, Inc. Morphogen induzierte nerven wiederherstellung und wiedergutmachung.

Also Published As

Publication number Publication date
ES2201059T5 (es) 2007-11-01
DE69333040D1 (de) 2003-07-17
JP4344012B2 (ja) 2009-10-14
JPH07509721A (ja) 1995-10-26
JP2009227679A (ja) 2009-10-08
PT653942E (pt) 2003-11-28
ES2201059T3 (es) 2004-03-16
EP0653942A1 (de) 1995-05-24
EP0653942B1 (de) 2003-06-11
DE69333040T3 (de) 2007-10-11
WO1994003200A1 (en) 1994-02-17
AU4797193A (en) 1994-03-03
DK0653942T3 (da) 2003-10-20
DE69333040T2 (de) 2004-05-06
CA2141554C (en) 2003-02-11
AU681594B2 (en) 1997-09-04
EP0653942B2 (de) 2007-03-07
CA2141554A1 (en) 1994-02-17
JP2005287512A (ja) 2005-10-20

Similar Documents

Publication Publication Date Title
DE69333040D1 (de) Morphogen induzierte nerven wiederherstellung und wiedergutmachung.
DK0670729T3 (da) Anvendelse af insulin-lignende vækstfaktorer og analoger til behandling af retinale nervesygdomme
DK1039802T3 (da) Transdermal terapeutisk anordning med capsicin og capsaicinanaloger
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
DK0661987T3 (da) Morphogeninduceret leverregeneration
DE58906649D1 (de) Implantierbares medizinisches Gerät mit Mitteln zum Stimulieren von Gewebekontraktionen mit einstellbarer Stimulationsintensität und Verfahren zum Betrieb eines solchen Gerätes.
ATE339956T1 (de) Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin
ES2152556T3 (es) Composiciones que contienen derivados del acido hidroperoxieicosatetraenoico y procedimientos de utilizacion en el tratamiento de trastornos de la sequedad ocular.
DE69222362D1 (de) Implantierbare Vorrichtung zur Herzrhythmuskorrektur, Herzreizung und Defibrillation mit unterschiedlichen Stimulationsfrequenzen zum unterstützen von Bradykardien
EP0348353A3 (en) The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases
ATE280758T1 (de) Mittel zum schutz von nervenzellen
EA200200847A1 (ru) Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов
ATE365550T1 (de) Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie
PT950057E (pt) Enantiomeros de 3-piridilo e sua utilizacao como analgesicos
ATE434975T1 (de) Vorrichtung und verfahren zur repositionierung von patienten
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
FR2760369B1 (fr) Stimulateur cardiaque multisites pour le traitement des insuffisances cardiaques par stimulation
Lund et al. Cortical reorganization and deafferentation in adult macaques
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
ATE359774T1 (de) Taurinderivate verwendbar in der behandlung von netzhauterkrankungen
NO20010390L (no) Behandling av angstsykdommer
Lee et al. Nerve growth factor expression in stroke induced rats after shock wave
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
CY1108922T1 (el) Θεραπεια μελανωματος

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0653942

Country of ref document: EP

REN Ceased due to non-payment of the annual fee